Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

NCT04978688 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Relugolix
DRUG: E2/NETA

Sponsor

Myovant Sciences GmbH